Joseph Keenan

After years of documentation and industry neglect, the World Health Organization (WHO) issued its first-ever

Two Japanese drugmakers and another in India were hit with Form 483s from the FDA following inspections that uncovered issues ranging from a lack of sanitary procedures to improper data collection

Gilead Sciences has issued a voluntary recall of one lot of COVID-19 antiviral Veklury, also known as remdesivir, after confirming "the presence of a glass particle" in a vial.

Symbiosis Pharmaceutical Services has shelled out £1.2 million ($1.57 million) to acquire a new manufacturing building at Castle Business Park in Stirling, Scotland, boosting the local CMO's production capacity by half.

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker's key semaglutide and insulin manufacturing plants this past spring.

The U.S. unit of Indian drugmaker Dr. Reddy's Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen.

The Government Accountability Office (GAO) issued a 67-page report that urges the FDA to begin implementing more aggressive steps to attract and

Unexo Life Sciences, an Indian drugmaker that manufactures a medicated patch for pain relief, has been hit with a

Indian drugmaker Lupin is recalling more than 600,000 bottles of the high blood pressure and heart failure drug ramipril due to the presence of an active pharmaceutical ingredient (API) that came from an unapproved vendor.

Indian drugmakers Aurobindo, Glenmark and Zydus have issued separate sweeping drug recalls over issues pertaining to impurities and labeling.